Table 4.
Summary of previous studies with lenvatinib plus pembrolizumab in patients with uterine carcinosarcoma.
| Study | Number of pts with UCS | Median follow-up (m) | ORR (%) | CBR (%) | Median PFS (%) | Median OS (%) |
|---|---|---|---|---|---|---|
| Hunt et al. 2021 | 7 | 2.8 | 0 | 28.5 | 2.6 | 2.8 |
| How et al., 2021/(overall) | 12/(70) | −/(7) | 25 | 58.3 | −/(4.6) | −/(8.6) |
| Zammarrelli et al., 2023/(overall) | 9/(43) | − | −/(32) | −/(73) | −/(6) | −/(18.3) |
| Our report | 5 | 9 | 40 | 60 | 9.1 | 10.2 |
pts, patients; UCS, uterine carcinosarcoma; m, months; ORR, overall response rate; CBR, clinical benefit rate; PFS, progression-free survival; OS, overall survival.